Sarah McCrea
Nurse Practitioner · Atlanta, GANPI 1275061228
Payments from drug & device makers
Across 111 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$298
- AstraZeneca$210
- Daiichi Sankyo Inc.$185
- AbbVie$176
- Pfizer$122
- Regeneron Healthcare Solutions, Inc.$119
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,08292%
- Education$1798%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 13 | $298 |
| AstraZeneca(2 entities) | 12 | $210 |
| Daiichi Sankyo Inc. | 10 | $185 |
| AbbVie | 7 | $176 |
| Pfizer | 6 | $122 |
| Regeneron Healthcare Solutions, Inc. | 5 | $119 |
| Incyte Corporation | 3 | $117 |
| Sanofi | 4 | $95 |
| Eisai Inc. | 5 | $94 |
| Novartis | 4 | $81 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $73 |
| Sobi, Inc | 4 | $67 |
| Karyopharm Therapeutics Inc. | 4 | $66 |
| Gilead(2 entities) | 4 | $66 |
| GSK | 3 | $59 |
| Amgen | 2 | $43 |
| Jazz Pharmaceuticals Inc. | 2 | $41 |
| Bayer | 2 | $40 |
| Seagen Inc. | 2 | $36 |
| Merck | 1 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Bristol Myers Squibb | 1 | $23 |
| Blueprint Medicines Corporation | 1 | $21 |
| Stemline Therapeutics Inc. | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $20 |
| Pharmaessentia USA Corporation | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Coherus Oncology, Inc. | 1 | $17 |
| Deciphera Pharmaceuticals Inc. | 1 | $15 |
| Dendreon Pharmaceuticals LLC | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Genentech USA, Inc. | 2 | $11 |
How this compares
$2,261 in reported general payments places this provider in the 85th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 26 | $417,618 |
| RevlimidLenalidomide | 21 | $379,744 |
| IbrancePalbociclib | 16 | $248,201 |
| VerzenioAbemaciclib | 16 | $196,324 |
| KisqaliRibociclib Succinate | 12 | $151,506 |
| EliquisApixaban | 54 | $54,286 |
| XareltoRivaroxaban | 22 | $28,089 |
| Exemestane | 28 | $3,384 |
| Letrozole | 110 | $2,549 |
| Anastrozole | 90 | $1,704 |
| Tamoxifen Citrate | 61 | $1,475 |
| Ondansetron Hcl | 31 | $1,279 |
| Gabapentin | 46 | $541 |
| Raloxifene Hcl | 13 | $452 |
| Olanzapine | 34 | $429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $117 | $417,61826 claims |
| Bristol Myers SquibbRevlimid | $23 | $379,74421 claims |
| PfizerIbrance, Eliquis | $122 | $302,48770 claims |
| NovartisKisqali | $81 | $151,50612 claims |
| Johnson & JohnsonXarelto | $298 | $28,08922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,328 nurse practitioner providers in Georgia.
Other nurse practitioner in Atlanta
- Janice McAlisterAtlanta$241K
- Laura ElledgeAtlanta$177K
- Casey MillerAtlanta$41K
- Kathryn InanAtlanta$17K
- Colby DoepelAtlanta$16K
- Mark HebertAtlanta$15K
- Ashley BlackmonAtlanta$13K
- Alexia CovingtonAtlanta$13K
- Marissa TorresAtlanta$12K
- Hayley TurnerAtlanta$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.